An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance - Full Text View

Purpose

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

Condition	Intervention	Phase
Glaucoma Ocular Hypertension	Drug: travoprost, latanoprost, or bimatoprost Drug: Additional ocular hypotensive medication	Phase IV

Genetics Home Reference related topics:

early-onset glaucoma

MedlinePlus related topics:

Glaucoma High Blood Pressure

ChemIDplus related topics:

Latanoprost Travoprost Bimatoprost

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Diagnostic, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Pharmacodynamics Study

Official Title:	An Evaluation of Use of Topical Ocular Hypotensive Medication by Electronic Compliance Measures

Further study details as provided by Robin, Alan L., M.D.:

Primary Outcome Measures:

Compliance.

Estimated Enrollment:	60
Study Start Date:	December 2005
Estimated Study Completion Date:	April 2006

Detailed Description:

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Currently using one or two topical ocular hypotensive medications

Exclusion Criteria:

Hypersensitivity to any component of medication

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00329095

Sponsors and Collaborators

Robin, Alan L., M.D.

Investigators


Principal Investigator:	Alan L. Robin, MD	Alan L. Robin, M.D.

More Information

Publications indexed to this study:

Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007 Oct;144(4):533-40. Epub 2007 Aug 8.

Study ID Numbers:	GMED-01
First Received:	May 19, 2006
Last Updated:	May 22, 2006
ClinicalTrials.gov Identifier:	NCT00329095
Health Authority:	United States: Institutional Review Board

Keywords provided by Robin, Alan L., M.D.:

Glaucoma

Compliance

Study placed in the following topic categories:

Bimatoprost

Glaucoma

Eye Diseases

Vascular Diseases

Latanoprost

Travoprost

Hypertension

Ocular Hypertension

Additional relevant MeSH terms:

Therapeutic Uses

Cardiovascular Diseases

Cardiovascular Agents

Antihypertensive Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on October 07, 2008

Sponsored by:	Robin, Alan L., M.D.
Information provided by:	Robin, Alan L., M.D.
ClinicalTrials.gov Identifier:	NCT00329095